BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Atopic dermatitis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for atopic dermatitis: 197 (109 sponsors; 46 newly posted in the last 180 days, 10 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 24.4, rank 14 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 31, Phase 2 62, Phase 3 50, Phase 4 3, N/A 51.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Pfizer PFE | 14 | NA 6, P1 1, P2 2, P3 5 | 4 | 2 |
| Sanofi SNY | 16 | NA 9, P3 4, P4 2, P2 1 | 2 | 4 |
| AbbVie ABBV | 9 | P2 2, NA 3, P3 4 | 1 | 4 |
| Keymed Biosciences Co.Ltd | 5 | P3 3, P2 2 | 0 | 1 |
| Almirall, S.A. | 4 | P3 3, NA 1 | 1 | 1 |
| Shanghai Mabgeek Biotech.Co.Ltd | 4 | P3 2, P2 2 | 1 | 1 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | 4 | P3 2, P1 2 | 2 | 0 |
| Jiangsu vcare pharmaceutical technology co., LTD | 3 | P3 2, P2 1 | 0 | 1 |
| Nektar Therapeutics NKTR | 3 | P2 1, P3 2 | 2 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 3 | P2 1, P3 2 | 0 | 2 |
| Eli Lilly and Company LLY | 2 | P3 2 | 0 | 0 |
| Otsuka Pharmaceutical Co., Ltd. | 2 | P3 2 | 0 | 2 |
| Akeso | 3 | P2 2, P3 1 | 0 | 0 |
| Galderma R&D | 3 | P2 1, NA 1, P3 1 | 2 | 0 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | 3 | P2 2, P3 1 | 0 | 0 |
| Incyte Corporation INCY | 3 | NA 2, P3 1 | 0 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 3 | P3 1, P2 1, P1 1 | 1 | 2 |
| Arcutis Biotherapeutics, Inc. ARQT | 2 | P3 1, P1 1 | 1 | 0 |
| EHL Bio Co., Ltd. | 2 | P2 1, P3 1 | 0 | 0 |
| Hangzhou Highlightll Pharmaceutical Co., Ltd new entrant | 2 | P2 1, P3 1 | 2 | 0 |
| LEO Pharma | 2 | P3 1, NA 1 | 1 | 0 |
| Beijing InnoCare Pharma Tech Co., Ltd. | 1 | P3 1 | 0 | 1 |
| E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Jiangsu Genscend Biopharmaceutical Co., Ltd | 1 | P3 1 | 0 | 1 |
| medac GmbH | 1 | P3 1 | 0 | 0 |
New-entrant sponsors: Hangzhou Highlightll Pharmaceutical Co., Ltd.
Recently stopped trials
- NCT06058156 Sanofi - terminated: Sponsor decision. Not related to safety concern. Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
- NCT07330934 Innovent Biologics (Suzhou) Co. Ltd. - terminated: Sponsor Decision A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
- NCT05486208 Eli Lilly and Company - terminated: Study terminated due to lack of efficacy signal in atopic dermatitis participants. A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis
- NCT06881251 Janssen Research & Development, LLC - terminated: Terminated: futility criteria met at interim efficacy analysis. A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
- NCT07408869 Candid Therapeutics - withdrawn: Sponsor decision A Phase 1 Study of Cizutamig in IgE Mediated Diseases
- NCT05882877 Amgen - terminated: Sponsor Decision A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With
- NCT05859724 Yellow Jersey Therapeutics AG - terminated: Asset acquisition by Johnson \& Johnson. Minimum study objectives necessary to inform safety, tolerability, and dose selection for Phase 2 d Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
- NCT06447506 GlaxoSmithKline - terminated: Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility cr Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
- NCT05999799 GlaxoSmithKline - terminated: Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified. A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Se
- NCT07146971 Good Molecules, LLC - terminated: We have decided to close the study due to recruitment challenges. Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-19 est. | P2 | Janssen Research & Development, LLC | NCT07230860 A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | active not recruiting | 189 |
| 2026-11-25 est. | P3 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT06775860 ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | recruiting | 552 |
| 2026-12 est. | P3 | Otsuka Pharmaceutical Co., Ltd. | NCT07173478 A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | Atopic Dermatitis (AD) | not yet recruiting | 156 |
| 2026-12 est. | P2 | Enveda Therapeutics | NCT07298395 Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis (AD) | recruiting | 105 |
| 2026-12-31 est. | P1/P2 | Bio-Thera Solutions | NCT06094179 Evaluate the Safety, Tolerability of BAT6026 | Dermatitis, Atopic | active not recruiting | 33 |
| 2027-01 est. | P3 | AbbVie ABBV | NCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe | Atopic Dermatitis | active not recruiting | 99 |
| 2027-01-05 est. | P3 | Shanghai Mabgeek Biotech.Co.Ltd | NCT07540442 A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | Dermatitis, Atopic | not yet recruiting | 180 |
| 2027-01-20 est. | P2/P3 | Turn Therapeutics TTRX | NCT07355075 A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermati | Eczema Atopic Dermatitis; Eczema; Atopic Dermatitis | recruiting | 190 |
| 2027-01-31 est. | P2 | Dermavon Holdings Limited | NCT07465120 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moder | Moderate to Severe Atopic Dermatitis | not yet recruiting | 160 |
| 2027-02 est. | P2 | AbbVie ABBV | NCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receivin | Hidradenitis Suppurativa; Atopic Dermatitis | recruiting | 60 |
| 2027-02 est. | P3 | Keymed Biosciences Co.Ltd | NCT07106372 A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | Atopic Dermatitis | not yet recruiting | 240 |
| 2027-02 est. | P3 | Otsuka Pharmaceutical Co., Ltd. | NCT07184645 A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | Atopic Dermatitis (AD) | not yet recruiting | 198 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-12 est. | P2 | Pfizer PFE | NCT05995964 A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 507 |
| 2026-11 est. | P2 | Apogee Therapeutics, Inc. APOG | NCT06395948 A Study Evaluating APG777 in Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 470 |
| 2026-11 est. | P3 | AbbVie ABBV | NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | Atopic Dermatitis | active not recruiting | 184 |
| 2026-11 est. | P3 | medac GmbH | NCT06239311 Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. | Moderate to Severe Atopic Dermatitis | recruiting | 277 |
| 2026-10-16 | P3 | LEO Pharma | NCT06311682 A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic D | Atopic Dermatitis | recruiting | 195 |
| 2026-10-09 | P3 | Regeneron Pharmaceuticals REGN | NCT02612454 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) | Atopic Dermatitis | completed | 880 |
| 2026-10 est. | P2 | Triveni Bio | NCT07167758 A Study Evaluating TRIV-509 in Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 95 |
| 2026-09-23 | P2 | Jiangsu Simcere Pharmaceutical Co., Ltd. | NCT07175233 A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis (AD) | active not recruiting | 184 |
| 2026-09-21 | P2 | Aclaris Therapeutics, Inc. ACRS | NCT07011706 ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis; Atopic; Dermatitis; AD; Eczema | active not recruiting | 110 |
| 2026-09 est. | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07211542 A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | recruiting | 75 |
| 2026-08-31 | P3 | Galderma R&D | NCT03989206 Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis | Moderate-to-Severe Atopic Dermatitis | completed | 1935 |
| 2026-08-30 est. | P3 | Keymed Biosciences Co.Ltd | NCT06495229 Study of CM310 in Adolescent Subjects With Atopic Dermatis | Atopic Dermatitis | active not recruiting | 180 |
| 2026-08-26 | P3 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT06468956 Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | completed | 652 |
| 2026-08-18 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07330934 A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | terminated | 18 |
| 2026-08-07 | P3 | Incyte Corporation INCY | NCT06832618 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 159 |
| 2026-07-23 | P2 | Evommune, Inc. EVMN | NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis | Atopic Dermatitis | completed | 121 |
| 2026-07-22 | P2 | Hoffmann-La Roche | NCT06863961 A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 162 |
| 2026-07-18 est. | P2 | Keymed Biosciences Co.Ltd | NCT06947980 Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | recruiting | 200 |
| 2026-07-13 | P2 | HK inno.N Corporation | NCT07073677 A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients | Mild to Moderate Atopic Dermatitis | recruiting | 162 |
| 2026-07-01 | P3 | Amgen AMGN | NCT05882877 A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (A | Atopic Dermatitis | terminated | 2621 |
| 2026-06-30 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT07042126 Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | recruiting | 180 |
| 2026-05-25 | P1/P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06324812 Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | completed | 128 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "atopic dermatitis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.